Anti-Gal9 antibodies significantly produce tumor regression of PDA cells injected subcutaneously into mice and increases survival in a KPC mice model that expresses Gal9 in cancer cells and some intratumoral myeloid cells [40]. This evidence concerns the gene LGALS9 and Patent ductus arteriosus.